Chimerix Inc (CMRX) Actualités

Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC...

Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose...

Form 4 - Statement of changes in beneficial ownership of securities

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16...

Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference

DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose...

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update

     – Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – –...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024

DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose...

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024...

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose...